Research & Clinical Trials
Servier Reports 37.2-Month Median PFS for VORANIGO in Crossover Glioma Patients at SNO 2026
By News Desk ·
Key takeaways
- Servier presented extended Phase 3 INDIGO follow-up at SNO 2026 covering 144 of 163 placebo patients who crossed over to VORANIGO.
- Median progression-free survival by investigator was 37.2 months among crossover patients overall.
- Average tumor volume rose 16.1% per six months before crossover and fell 2.9% per six months after it.
- Servier completed its $2.5 billion acquisition of Day One Biopharmaceuticals in April 2026, adding OJEMDA.
Servier reported a median progression-free survival of 37.2 months among glioma patients who crossed over from placebo to VORANIGO (vorasidenib) in the Phase 3 INDIGO trial, according to extended follow-up presented at the 31st Society for Neuro-Oncology Annual Meeting in Philadelphia. The findings were announced by PR Newswire on November 17, 2026.
What the INDIGO Crossover Data Showed
The updated results cover 144 of 163 patients randomized to placebo who crossed over to VORANIGO by the January 17, 2025 data cutoff, along with analyses by histology in oligodendroglioma and astrocytoma. Median PFS per investigator was 37.2 months overall (95% CI, 33.4-not estimable). Among patients with astrocytoma who crossed over, median PFS was 37.2 months (95% CI, 25.6-NE); in oligodendroglioma it was not reached (95% CI, 24.6-NE). Median PFS was 33.4 months (95% CI, 24.6-NE) for patients with progressive disease at crossover and not estimable for those without.
In a post-hoc analysis, average tumor volume increased by 16.1% per six months before crossover and decreased by 2.9% per six months after crossover, a shift seen in both histology subgroups. Objective response rate by blinded independent review committee rose from 10.7% in September 2022 to 20.8% in January 2025 in the overall population. Grade 3 or higher treatment-emergent adverse events occurred in 31.7% of patients randomized to VORANIGO and 20.1% of those who crossed over, with no new safety signals and no treatment-related deaths.
"The results from the INDIGO analyses presented at SNO reinforce the clinical benefit of VORANIGO in patients with Grade 2 IDH-mutant glioma, with the crossover patient population data demonstrating consistent results," said Islam Hassan, M.D., MSc., Global Head of Development, Neuro-Oncology at Servier.
Seizure Control and Quality of Life Findings
An exploratory analysis presented by Wolfgang Wick, M.D., of Universitätsklinikum Heidelberg & German Cancer Research Center, examined seizure activity and quality of life. The proportion of VORANIGO-treated patients with on-treatment seizures remained stable from March 2023 to January 2025, at 98.1% versus 98.2%. The seizure rate fell from 18.2 to 15.9 seizures per person-year, and the rate ratio versus placebo improved from 0.36 to 0.28. On the FACT-Br scale, patients with more than one seizure showed a lower risk of worsening versus placebo (HR=0.38; 95% CI, 0.15-1.00).
Servier's Oncology Build-Out
Servier is an independent French pharmaceutical group governed by a non-profit foundation, founded in 1954 and headquartered in Suresnes, France, according to akta.pro company records. The same records show Servier completed its acquisition of Day One Biopharmaceuticals for $2.5 billion in April 2026, adding OJEMDA (tovorafenib), an FDA-approved treatment for pediatric low-grade glioma. Servier has set a €10 billion revenue target for 2030, with €4 billion from oncology.
Earlier Glioma Presentations at SNO 2026
On November 6, 2026, Servier said it would present nine abstracts at SNO 2026, including five oral presentations on its glioma portfolio, PR Newswire reported. On October 21, 2026, Okomera announced a commercial agreement with Servier to use its tumor miniaturization technology for cancer research, focusing on pancreatic cancer and glioblastoma, according to FinancialContent Business Page.
What Comes Next for VORANIGO
The INDIGO analyses were presented as oral presentations on November 14 and November 15, 2026. Servier's U.S. prescribing information for VORANIGO was revised in June 2026.